Buenos Aires

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Amyloidosis5 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• High blood pressure1 trial
• Metastatic breast cancer1 trial
• Neuromyelitis optica (NMOSD)1 trial
• Obesity1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 38 trials
• Phase 1/21 trial

Status

• Recruiting4 trials
• Active, not recruiting3 trials
• Completed2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Alnylam Pharmaceuticals7 trials
• Alexion Pharmaceuticals, Inc.1 trial
• Olema Pharmaceuticals, Inc.1 trial
• Syndax Pharmaceuticals1 trial

Running trials

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

  Contact: Syndax Pharmaceuticals

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

  NCT06845202· Phase 1/2· Alnylam Pharmaceuticals· Source

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

  Contact: Pablo Lopez

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• High blood pressure1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting

Closed trials

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source